Which companies face a material regulatory financing or launch risk, and where should the fund intervene first?
The visibility gap
What is a portfolio regulatory risk review?
A portfolio regulatory risk review applies one evidence and confidence framework across multiple physical-product companies. One company may report a certificate, another a test booking and another a launch date. Without a common method, the fund cannot tell whether those statements describe comparable readiness—or whether the next round contains an avoidable regulatory surprise.
Illustrative portfolio view
A risk matrix designed for action, not technical completeness.
The fictional example shows the type of portfolio-level comparison the review can support. Company names and findings are invented and do not represent clients or completed engagements.
Operating model
Triage the portfolio, then deepen only where the decision warrants it.
Collect a controlled set of product, route, evidence, budget and timeline facts from each company.
Normalize findings into common confidence and exposure levels while preserving category-specific nuance.
Identify companies needing a deeper Deal Gate, specialist opinion or immediate board action.
Turn material gaps into milestones that can be revisited in the next operating or board cycle.
Board output
Give partners a concise exposure map and management teams a usable action list.
Portfolio heat map
Comparable exposure levels, confidence and priority across the assessed companies.
Company action pages
Material findings, evidence requests, owner, timing and the consequence of non-resolution.
Intervention plan
Where to provide specialist support, reserve capital, change a milestone or seek further evidence.
Scope boundary
A portfolio screen is a prioritization tool, not a certification audit.
Findings remain indicative and depend on the scope and evidence supplied by each company. A screen may recommend a deeper product-specific review, legal advice or formal work by an appropriately qualified body.